Purushothaman Athul M, Pujari Vinayak Seenappa, Kadirehally Nalini B, Bevinaguddaiah Yatish, Reddy Pratheek R
Department of Anaesthesiology, Ramaiah Medical College and Hospitals, Bengaluru, Karnataka, India.
Saudi J Anaesth. 2018 Apr-Jun;12(2):198-203. doi: 10.4103/sja.SJA_409_17.
Dexamethasone is a potent corticosteroid when administered alone or in combination alone has proven efficacious in preventing nausea and vomiting (PONV) perioperatively. However, the administration of even a single dose has been associated with hyperglycemia. This is the first study that evaluates the effect of two low-doses of dexamethasone (4 and 8 mg) on blood glucose concentrations among diabetics and nondiabetics in patients who have received spinal anesthesia.
After obtaining ethical clearance and patient consent, 180 American Society of Anesthesiologists 1-3 patients undergoing the elective infraumbilical surgeries under spinal anesthesia aged between 18 and 70 years were included in this study. Ninety diabetic patients were allotted to the diabetic group (DM), and ninety nondiabetic patients were allotted to the nondiabetic group (ND). Group DM was divided into three subgroups DM0, DM4, and DM8. Group ND was divided into three subgroups ND0, ND4, and ND8. The patients in groups DM0 and ND0 served as controls. The patients in groups DM4 and ND4 received 4 mg dexamethasone. The patients in groups DM8 and ND8 received 8 mg dexamethasone. The blood glucose concentrations were monitored at 0 (baseline), 1, 2, 3, 4, 5, 6, and 8 h after giving the drug.
The baseline blood glucose values were higher in diabetics compared to nondiabetics (128.57 ± 22.26 vs 94.99 ± 12.82 mg/dL). There was a statistically significant increase in blood glucose concentrations in both diabetics and nondiabetics who received dexamethasone. The rise of blood glucose from baseline was similar in both diabetics and nondiabetics.
The maximum rise in blood glucose was in the range of 40-45 mg/dl in the patients who received dexamethasone. The clinician should use his clinical judgment before administering dexamethasone for PONV prophylaxis/treatment.
地塞米松是一种强效皮质类固醇,单独使用或联合使用时已被证明在围手术期预防恶心和呕吐(PONV)方面有效。然而,即使单次给药也与高血糖有关。这是第一项评估两种低剂量地塞米松(4毫克和8毫克)对接受脊髓麻醉的糖尿病患者和非糖尿病患者血糖浓度影响的研究。
在获得伦理批准和患者同意后,本研究纳入了180例年龄在18至70岁之间、接受脊髓麻醉下择期脐下手术的美国麻醉医师协会1-3级患者。90例糖尿病患者被分配到糖尿病组(DM),90例非糖尿病患者被分配到非糖尿病组(ND)。DM组分为三个亚组DM0、DM4和DM8。ND组分为三个亚组ND0、ND4和ND8。DM0组和ND0组的患者作为对照。DM4组和ND4组的患者接受4毫克地塞米松。DM8组和ND8组的患者接受8毫克地塞米松。给药后0(基线)、1、2、3、4、5、6和8小时监测血糖浓度。
糖尿病患者的基线血糖值高于非糖尿病患者(128.57±22.26 vs 94.99±12.82毫克/分升)。接受地塞米松的糖尿病患者和非糖尿病患者的血糖浓度均有统计学显著升高。糖尿病患者和非糖尿病患者血糖从基线的升高相似。
接受地塞米松的患者血糖的最大升高范围为40-45毫克/分升。临床医生在使用地塞米松预防/治疗PONV之前应运用临床判断力。